Skip to main content

Table 3 Baseline characteristics of efficacy measurements of patients receiving TSC and placebo

From: Treatment of migraines with Tianshu capsule: a multi-center, double-blind, randomized, placebo-controlled clinical trial

CharacteristicsTSC (N = 750)Placebo (N = 250)P values
Times of headache attacks, mean ± SD, no.4.01 ± 1.143.93 ± 1.150.2896
Headache duration, mean ± SD, h8.26 ± 7.448.66 ± 8.750.4915
VAS of headache, mean ± SD5.10 ± 1.415.00 ± 1.350.2940
Days of acute analgesic use, mean ± SD, d2.55 ± 1.812.49 ± 1.850.6744
Nausea, mean ± SD, no.3.59 ± 1.533.58 ± 1.490.6703
Vomiting, mean ± SD, no.1.78 ± 1.951.76 ± 1.920.8831
Photophobia, mean ± SD, no.2.02 ± 1.822.09 ± 1.840.6059
Phonophobia, mean ± SD, no.1.40 ± 1.711.28 ± 1.620.4308
  1. d day, no. number, SD Standard deviation, VAS Visual analogue score